New Research: Access and quality implications of CMS proposed Part B model
Issue brief adds to concerns proposed Part B Drug Payment Model lacks safeguards to protect patients from access barriers and reduced quality of care.
Issue brief adds to concerns proposed Part B Drug Payment Model lacks safeguards to protect patients from access barriers and reduced quality of care.
In recent weeks, providers and stakeholders across the health care system have raised concerns that the Part B Drug Payment Model proposed by the Centers for Medicare & Medicaid Services (CMS) lacks needed safeguards to protect patients from access barriers and reduced quality of care. A new issue brief released by Discern Health last week builds on these concerns, finding CMS has not yet presented a monitoring and evaluation plan for the Part B Drug Payment Model to mitigate the risk of harm to Medicare beneficiary access and quality of care.
CMS’ proposed Part B Drug Payment Model would be run by the Center for Medicare and Medicaid Innovation (CMMI). CMMI was set up to test new payment and delivery models and is required to evaluate each model to understand the impact on quality of care (including patient outcomes) and changes in program spending. This evaluation – and ongoing monitoring for unintended effects – is very important to ensure that Medicare patients are not harmed by any changes to the Medicare program.
Discern Health identified several gaps and risks in the Part B Drug Payment Model design, including: